MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- STRIDES SHASUN LIMITED (pharmaceuticals)
- STRIDES SHASUN LIMITED Financial Data
STRIDES PHARMA SCIENCE Fact Sheet 
(PLLB)
Here is the latest financial fact sheet of STRIDES PHARMA SCIENCE. For more details, see the STRIDES PHARMA SCIENCE quarterly results and STRIDES PHARMA SCIENCE share price and chart. For a sector overview, read our pharmaceuticals sector report.
STRIDES PHARMA SCIENCE Price History
| % ch | % | 0.6 |
| No. of shares | m | 59.65 |
| % ch week | % | 9.2 |
| % ch 1-mth | % | 2.0 |
| % ch 12-mth | % | -41.0 |
| 52 week H/L | Rs | 855.2/334.1 |
STRIDES PHARMA SCIENCE Financials
| No. of Mths Year Ending |
15 Mar-14* |
12 Mar-15* |
12 Mar-16* |
12 Mar-17* |
12 Mar-18* |
5-Yr Chart Click to enlarge
|
|---|
| STRIDES PHARMA SCIENCE EQUITY SHARE DATA | |||||||
|---|---|---|---|---|---|---|---|
| High | Rs | 1,138 | 1,199 | 1,413 | 1,275 | 1,147 | |
| Low | Rs | 344 | 384 | 848 | 918 | 642 | |
| Sales per share (Unadj.) | Rs | 225.1 | 200.6 | 320.3 | 308.1 | 317.2 | |
| Earnings per share (Unadj.) | Rs | 296.6 | 141.7 | 13.2 | 31.3 | 7.8 | |
| Diluted earnings per share | Rs | 296.2 | 141.7 | 19.8 | 46.9 | 11.8 | |
| Cash flow per share (Unadj.) | Rs | 306.1 | 152.5 | 27.9 | 45.4 | 25.1 | |
| Dividends per share (Unadj.) | Rs | 505.00 | 108.00 | 5.00 | 4.50 | 2.00 | |
| Adj. dividends per share | Rs | 504.32 | 107.95 | 7.49 | 6.75 | 3.00 | |
| Dividend yield (eoy) | % | 68.2 | 13.7 | 0.4 | 0.4 | 0.2 | |
| Book value per share (Unadj.) | Rs | 169.0 | 193.9 | 297.5 | 307.4 | 274.3 | |
| Adj. book value per share | Rs | 168.8 | 193.8 | 445.6 | 460.8 | 411.5 | |
| Shares outstanding (eoy) | m | 59.57 | 59.62 | 89.35 | 89.42 | 89.50 | |
| Bonus/Rights/Conversions | ESOP | ESOP | ESOP | ESOP | ESOP | ||
| Price / Sales ratio | x | 3.3 | 3.9 | 3.5 | 3.6 | 2.8 | |
| Avg P/E ratio | x | 2.5 | 5.6 | 85.5 | 35.1 | 114.0 | |
| P/CF ratio (eoy) | x | 2.4 | 5.2 | 40.5 | 24.2 | 35.7 | |
| Price / Book Value ratio | x | 4.4 | 4.1 | 3.8 | 3.6 | 3.3 | |
| Dividend payout | % | 170.3 | 76.2 | 37.8 | 14.4 | 25.5 | |
| Avg Mkt Cap | Rs m | 44,135 | 47,165 | 100,988 | 98,036 | 80,058 | |
| No. of employees | `000 | 1.5 | 2.0 | 4.7 | 5.8 | 2.5 | |
| Total wages/salary | Rs m | 1,572 | 1,721 | 3,577 | 4,192 | 4,341 | |
| Avg. sales/employee | Rs Th | 8,939.5 | 5,979.3 | 6,102.8 | 4,750.8 | 11,325.8 | |
| Avg. wages/employee | Rs Th | 1,047.9 | 860.3 | 762.7 | 722.7 | 1,731.4 | |
| Avg. net profit/employee | Rs Th | 11,778.3 | 4,225.0 | 251.9 | 482.2 | 280.1 | |
| STRIDES PHARMA SCIENCE INCOME DATA | |||||||
|---|---|---|---|---|---|---|---|
| Net Sales | Rs m | 13,409 | 11,959 | 28,622 | 27,554 | 28,394 | |
| Other income | Rs m | 602 | 386 | 921 | 1,611 | 941 | |
| Total revenues | Rs m | 14,012 | 12,344 | 29,543 | 29,165 | 29,334 | |
| Gross profit | Rs m | 2,234 | 2,289 | 4,140 | 5,274 | 3,965 | |
| Depreciation | Rs m | 565 | 640 | 1,313 | 1,262 | 1,540 | |
| Interest | Rs m | 1,089 | 474 | 1,682 | 1,831 | 1,962 | |
| Profit before tax | Rs m | 1,183 | 1,560 | 2,067 | 3,792 | 1,403 | |
| Minority Interest | Rs m | -6 | 6 | 0 | 0 | 0 | |
| Prior Period Items | Rs m | 0 | 0 | -47 | 4 | -168 | |
| Extraordinary Inc (Exp) | Rs m | 19,736 | 8,361 | -414 | -364 | -436 | |
| Tax | Rs m | 3,245 | 1,476 | 425 | 634 | 97 | |
| Profit after tax | Rs m | 17,667 | 8,450 | 1,181 | 2,797 | 702 | |
| Gross profit margin | % | 16.7 | 19.1 | 14.5 | 19.1 | 14.0 | |
| Effective tax rate | % | 274.3 | 94.6 | 20.5 | 16.7 | 6.9 | |
| Net profit margin | % | 131.8 | 70.7 | 4.1 | 10.2 | 2.5 | |
| STRIDES PHARMA SCIENCE BALANCE SHEET DATA | |||||||
|---|---|---|---|---|---|---|---|
| Current assets | Rs m | 13,086 | 14,447 | 35,149 | 37,918 | 24,836 | |
| Current liabilities | Rs m | 7,074 | 10,022 | 18,920 | 31,039 | 18,993 | |
| Net working cap to sales | % | 44.8 | 37.0 | 56.7 | 25.0 | 20.6 | |
| Current ratio | x | 1.8 | 1.4 | 1.9 | 1.2 | 1.3 | |
| Inventory Days | Days | 48 | 63 | 78 | 97 | 71 | |
| Debtors Days | Days | 99 | 112 | 132 | 132 | 113 | |
| Net fixed assets | Rs m | 5,506 | 8,400 | 35,682 | 37,639 | 34,289 | |
| Share capital | Rs m | 596 | 596 | 894 | 894 | 895 | |
| "Free" reserves | Rs m | 4,594 | 10,962 | 25,685 | 26,594 | 23,651 | |
| Net worth | Rs m | 10,068 | 11,558 | 26,579 | 27,488 | 24,546 | |
| Long term debt | Rs m | 2,755 | 2,530 | 26,270 | 16,377 | 15,513 | |
| Total assets | Rs m | 20,990 | 24,805 | 74,559 | 81,050 | 65,437 | |
| Interest coverage | x | 2.1 | 4.3 | 2.2 | 3.1 | 1.7 | |
| Debt to equity ratio | x | 0.3 | 0.2 | 1.0 | 0.6 | 0.6 | |
| Sales to assets ratio | x | 0.6 | 0.5 | 0.4 | 0.3 | 0.4 | |
| Return on assets | % | 89.4 | 36.0 | 3.8 | 5.7 | 4.1 | |
| Return on equity | % | 175.5 | 73.1 | 4.4 | 10.2 | 2.9 | |
| Return on capital | % | 171.6 | 73.8 | 6.2 | 12.0 | 6.9 | |
| Exports to sales | % | 59.4 | 60.2 | 53.1 | 0 | 0 | |
| Imports to sales | % | 20.5 | 23.5 | 15.9 | 0 | 0 | |
| Exports (fob) | Rs m | 7,959 | 7,204 | 15,192 | 0 | 0 | |
| Imports (cif) | Rs m | 2,752 | 2,809 | 4,565 | 0 | 0 | |
| Fx inflow | Rs m | 22,791 | 13,031 | 16,612 | 13,465 | 15,697 | |
| Fx outflow | Rs m | 3,088 | 3,165 | 5,292 | 4,076 | 735 | |
| Net fx | Rs m | 19,703 | 9,865 | 11,320 | 9,389 | 14,962 | |
| STRIDES PHARMA SCIENCE CASH FLOW | |||||||
|---|---|---|---|---|---|---|---|
| From Operations | Rs m | -2,717 | 834 | 733 | 2,881 | 1,871 | |
| From Investments | Rs m | 40,771 | 519 | -22,248 | -6,867 | 5,826 | |
| From Financial Activity | Rs m | -33,185 | -4,213 | 29,439 | 3,382 | -10,157 | |
| Net Cashflow | Rs m | 4,869 | -2,860 | 7,924 | -603 | -2,615 | |
Share Holding
|
Company Information
|
|||||||||||||||||||||||||||||||||||||||||
| CHM: Deepak Vaidya (MD) | COMP SEC: Badree Komandur (EVP-Finance) | YEAR OF INC: 1980 | BSE CODE: 532531 | FV (Rs): 10 | DIV YIELD (%): 0.6 |
Read: STRIDES SHASUN LTD 2017-18 Annual Report Analysis
More Pharmaceuticals Company Fact Sheets: DIVIS LABORATORIES BIOCON LTD WOCKHARDT LTD. FULFORD INDIA AUROBINDO PHARMA
Compare STRIDES PHARMA SCIENCE With: DIVIS LABORATORIES BIOCON LTD WOCKHARDT LTD. FULFORD INDIA AUROBINDO PHARMA
Compare STRIDES PHARMA SCIENCE With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
|
| |
Today's Market
Indian Indices Recover; Sensex Ends 77 Points Higher(Closing)
Indian share markets witnessed buying interest during closing hours and ended on a positive note. Gains were seen in the metal sector.
Views on news
STRIDES PHARMA SCIENCE Announces Quarterly Results (2QFY19); Net Profit Down 72.2% (Quarterly Result Update)
Nov 6, 2018 | Updated on Nov 6, 2018For the quarter ended September 2018, STRIDES PHARMA SCIENCE has posted a net profit of Rs 54 m (down 72.2% YoY). Sales on the other hand came in at Rs 7 bn (down 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.
STRIDES SHASUN LTD 2017-18 Annual Report Analysis (Annual Result Update)
Oct 1, 2018 | Updated on Oct 1, 2018Here's an analysis of the annual report of STRIDES SHASUN LTD for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of STRIDES SHASUN LTD. Also includes updates on the valuation of STRIDES SHASUN LTD.
STRIDES SHASUN LTD Announces Quarterly Results (1QFY19); Net Profit Down 57.5% (Quarterly Result Update)
Aug 10, 2018 | Updated on Aug 10, 2018For the quarter ended June 2018, STRIDES SHASUN LTD has posted a net profit of Rs 38 m (down 57.5% YoY). Sales on the other hand came in at Rs 7 bn (down 21.2% YoY). Read on for a complete analysis of STRIDES SHASUN LTD's quarterly results.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
Shalby Ltd. (IPO)
Dec 2, 2017Should you subscribe to the IPO of Shalby Ltd?
More Views on NewsMost Popular
It's Almost the Perfect Time to Buy This Safe Stock(The 5 Minute Wrapup)
Dec 6, 2018My latest StockSelect recommendation ticks all the boxes of a great safe stock.
Patel's Exit, Election Results, and 4 'Must Have' Small Caps in These Exceptional Times(Profit Hunter)
Dec 11, 2018RBI Governor's resignation is a statement of dissent with the way government is handling the economy's affairs and could lead to some serious market correction. Here's how to make the most of it.
Players in an Oligopoly Should Have Financials Like This(Chart Of The Day)
Dec 7, 2018This stock has corrected 30% from peak and looks attractive at these valuations.
Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)
Dec 5, 2018Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.
DSP Mutual Fund's Sale of DHFL Bonds: Here's What You Need to Know(Outside View)
Dec 5, 2018PersonalFN explains the probable reason as to why the capital market regulator has initiated DSP Mutual Fund's bond sale that caused DHFL stock to crash.
More|
| |
TRACK STRIDES PHARMA SCIENCE
- Track your investment in STRIDES PHARMA SCIENCE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON STRIDES PHARMA SCIENCE
STRIDES PHARMA SCIENCE - TEVA PHARMA COMPARISON
COMPARE STRIDES PHARMA SCIENCE WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.